Safety/Tolerability Study of AV-412 in Subjects With Refractory or Relapsed Solid Tumor Malignancies
Status:
Terminated
Trial end date:
2010-02-01
Target enrollment:
Participant gender:
Summary
AV-412 is a new oral therapy developed to inhibit the growth of solid tumors in patients who
have not responded to standard therapy or surgical interventions, or who have experienced
relapse. This study will test the safety of AV-412 and determine the maximum tolerated dose
for the treatment of solid tumors.